The effect of CA125 on metastasis of ovarian cancer: old marker new function
Metrics: PDF 2307 views | HTML 3144 views | ?
Qin Yuan1,*, Jiayin Song2,*, Weiwei Yang3, Hongyan Wang1, Qianyu Huo1, Jie Yang1, Xiaoxu Yu3, Yunde Liu1, Chen Xu4 and Huijing Bao1
1School of Laboratory Science, Tianjin Medical University, Tianjin, China
2The Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3The Department of Laboratory Science, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China
4The Department of Laboratory Science, Tianjin Fourth Central Hospital, Tianjin, China
*These authors have contributed equally to this work
Huijing Bao, email: [email protected]
Chen Xu, email: [email protected]
Yunde Liu, email: [email protected]
Keywords: ovarian cancer, metastasis, CA125, Wnt pathway, cut-off value
Received: September 30, 2016 Accepted: May 04, 2017 Published: June 07, 2017
CA125 has been used extensively to screen for neoplasms, especially in ovarian cancer. The serum CA125 level can be used as a better prognosis evaluation and it may dynamic monitoring the disease progression. We explored the effect of CA125 on ovarian cancer cell migration and its underlying mechanism. Transwell assays showed that exposure to 0.2 μg/ml or 0.4 μg/ml CA125 for 48 h increased migration of A2780 and OVCAR-3 ovarian cancer cells. This effect of CA125 was blocked addition of 200 ng/ml DKK-1, a Wnt pathway inhibitor. Conversely, addition of CA125 reversed the inhibitory effect of Wnt inhibition in A2780 cells pretreated with DKK-1. Examination of CA125 levels in serum from 97 ovarian cancer patients revealed no relationship between a patient’s age or CA125 level currently used clinically for ovarian cancer diagnosis and metastasis. However, using receiver operating characteristic (ROC) curves, we identified a new cut-off value for the serum CA125 concentration (82.9 U/ml) that is predictive of metastasis. The area under the curve is 0.632. This new cut-off value has the potential to serve as a clinically useful indicator of metastasis in ovarian cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.